Clinical Trials Logo

Gastric Ulcer clinical trials

View clinical trials related to Gastric Ulcer.

Filter by:

NCT ID: NCT00173953 Completed - Dyspepsia Clinical Trials

Lymphocytic Subsets and Cytokine Production With H. Pylori Infection

Start date: January 2001
Phase: N/A
Study type: Interventional

The aims of this study are 1) to determine the cytokines produced by both Th1 and Th2 subsets in gastric antral biopsy specimens from Taiwanese patients before and after anti H. pylori therapy; 2) to obtain a detailed phenotypic characterization and distribution pattern of mucosal lymphocytes in H. pylori-associated gastritis and to define possible contributing immune mechanisms responsible for the chronicity of the disease and its associated lesions.

NCT ID: NCT00153673 Completed - Arthritis Clinical Trials

Effect of Selective COX-2 Inhibition on Ulcer Healing

Start date: February 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effect of Famotidine plus a COX-2 inhibitor (celecoxib) with Famotidine plus dologesics in ulcer healing in arthritis patients.

NCT ID: NCT00149084 Recruiting - Gastritis Clinical Trials

Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori

Start date: April 2003
Phase: Phase 3
Study type: Interventional

The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.

NCT ID: NCT00132171 Completed - Clinical trials for Helicobacter Pylori Infection

Helicobacter Pylori Eradication With a New Sequential Treatment

Start date: January 2001
Phase: Phase 3
Study type: Interventional

Eradication rates of Helicobacter pylori (H. pylori) with standard triple therapy are disappointing, and studies from several countries confirm this poor performance. The study aimed to assess the eradication rate of a new sequential treatment regimen compared with conventional triple therapy for the eradication of H. pylori infection.